Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

计划入组 72 人 · 首次发布于 2024 年 11 月 13 日

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

计划入组 17 人 · 首次发布于 2021 年 12 月 30 日

Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy

计划入组 15 人 · 首次发布于 2026 年 5 月 26 日

Sparsentan(Filspari)

C₃₂H₄₀N₄O₅S

intravenous immunoglobulin (primary immunodeficiency disease)

immunoglobulin A antibody

PRIMARY PHARMACEUTICALS, INC.

United States

PRIMARY HEALTH CARE CORPORATION

Qatar

Southcoast Center For Primary & Specialty Care

United States

Calliditas Therapeutics Presents New NefIgArd Trial Data Supporting Nefecon's Gut-Targeted Mechanism in IgA Nephropathy

Taiwan TFDA Approves Nefecon for Primary IgA Nephropathy Treatment

FDA Grants Accelerated Approval to Otsuka's Voyxact for IgA Nephropathy, First APRIL-Targeting Therapy